Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cilo Cybin HoldingsJSE:CCC 11 Equity-to-Asset is 0.92 as of Sep. 2025, which is at its 10-year median of 0.92. GuruFocus rates JSE:CCC with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,005 Drug Manufacturers companies, Cilo Cybin Holdings ranks better than 95.62% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Cilo Cybin Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2025 was R100.17 Mil. Cilo Cybin Holdings's Total Assets for the quarter that ended in Sep. 2025 was R108.94 Mil.
Therefore, Cilo Cybin Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2025 was 0.92.
The historical rank and industry rank for Cilo Cybin Holdings's Equity-to-Asset or its related term are showing as below:
JSE:CCC'
s Equity-to-Asset Range Over the Past 10 Years
Min: -7.04 Med: 0.92 Max: 1
Current: 0.92
During the past 4 years, the highest Equity to Asset Ratio of Cilo Cybin Holdings was 1.00. The lowest was -7.04. And the median was 0.92.
JSE:CCC's Equity-to-Asset is ranked better than 95.62% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs JSE:CCC: 0.92
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Cilo Cybin Holdings Equity-to-Asset Related Terms
Cilo Cybin Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Cilo Cybin Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:CCC vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cilo Cybin Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cilo Cybin Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cilo Cybin Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Cilo Cybin Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Cilo Cybin Holdings's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cilo Cybin Holdings (JSE:CCC) has a Equity-to-Asset of 0.92 as of Sep. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cilo Cybin Holdings and its competitors. This is near median its historical median of 0.92. According to the industry distribution chart, Cilo Cybin Holdings ranks #44 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 4.4%.
Is Cilo Cybin Holdings' Equity-to-Asset too high?
Cilo Cybin Holdings' current Equity-to-Asset of 0.92 is near median its 10-year median of 0.92. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Cilo Cybin Holdings' value of 0.92 is 50.8% above this industry median. Based on the distribution chart, Cilo Cybin Holdings ranks #44 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cilo Cybin Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cilo Cybin Holdings' Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cilo Cybin Holdings ranks #44 out of 1005 companies for Equity-to-Asset. This places Cilo Cybin Holdings in the top 4% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.61. Cilo Cybin Holdings' value of 0.92 is 50.8% above this benchmark. While the company's 10-year median is 0.92 vs. the industry median of 0.61, Cilo Cybin Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cilo Cybin Holdings's current Equity-to-Asset of 0.92 is 50.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Cilo Cybin Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cilo Cybin Holdings's current Equity-to-Asset is 0.92, which is near median its own 10-year median of 0.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cilo Cybin Holdings stock overvalued right now?
Cilo Cybin Holdings (JSE:CCC) has a current Equity-to-Asset of 0.92. The current Equity-to-Asset is 0.92, which is near median its 10-year median of 0.92 and 50.8% above the Drug Manufacturers industry median of 0.61. Cilo Cybin Holdings' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Cilo Cybin Holdings (JSE:CCC), the current Equity-to-Asset is 0.92 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cilo Cybin Holdings Ltd is engaged in identifying viable investments in Biotech, Biohacking and Pharmaceutical businesses. It offers products and services in the medical cannabis sector.
11GF Score
Get the complete analysis for JSE:CCC
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:CCC has been successfully added to your 
